达纳康抗高血压脑小动脉硬化与预防脑卒中的初步观察  

Preliminery investigation on effect of Tanakon upon prevention and treatment of hypertensive arteriolar sclerosis and stroke.

作　　者：方燕南[1] 张艳[1] 黄如训[1] 洪华[1] 

机构地区：[1]中山医科大学附属第一医院神经科

出　　处：《中国神经精神疾病杂志》1998年第4期208-210,共3页Chinese Journal of Nervous and Mental Diseases

摘　　要：目的观察达纳康对高血压脑小动脉硬化的作用及预防脑卒中的效果。方法采用肾血管性高血压大鼠（ＲＨＲ）模型，选择与高血压动脉硬化相关的有害因子ＡⅠ、ＡⅡ、ＡＬＤ、ＥＴ及具有扩张血管作用的ＳＯＤ和ｃＧＭＰ，观察其在高血压形成的早期和晚期分别给于达纳康口服后的改变及与高血压脑小动脉硬化的关系。结果高血压组和晚期喂药组动脉硬化较严重，ＡⅠ、ＡⅡ、ＡＬＤ、ＥＴ均接近正常组水平，ＳＯＤ和ｃＧＭＰ增多。结论尽早防治高血压小动脉硬化可减少脑卒中的发生。Objective To observe the changes in hypertensive cerebral arteriosclerosis and incidence of stroke after applying Tannkon. Methods Using the renovascular hypertensive rats (RHR) as animal model, we have investigated the changes in the blood levels of the hypertensive arteriosclerosis-associated factors, AI, AII, ALD, ET as well as the changes in the vassdilating SOD and cGMP after respective oral administration of Tannkon in an early and late stage of hypertensive period. Results It was shown that arteriosclerosis was more severe in both RHR and late treated groups, with a marked elevation in AI, AII, ALD and ET compared with the corresponding values in the early treated group. Arteriosclerosis changes in the early treated group was lessened. The blood levels of AI, AII, ALD and ET in this group nearly decreased to their corresponding levels in the normal control group. A rise of blood levels of SOD and cGMP was also seen in the early treated group. Conclusions These results reveal that it was important to treat early hypertension as soon as possible in the reduction of cerebral stroke.

关 键 词：达纳康 高血压 脑小动脉硬化 药物疗法 中风 

分 类 号：R972[医药卫生—药品] R743.305[医药卫生—药学]